1. Volume 139, Issue 2, Pages 491-498 (August 2010)
Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B 
Jurriën G.P. Reijnders, Moniek J. Perquin, Ningping Zhang, Bettina E. Hansen, Harry L.A. Janssen 
Gastroenterology 
Volume 139, Issue 2, Pages (August 2010)
DOI: /j.gastro
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Kaplan–Meier curve for the cumulative probabilities of achieving HBeAg seroconversion during nucleos(t)ide analogue therapy. (A) Number of patients who have not achieved HBeAg seroconversion and are still in follow-up evaluation. (B) Number of patients who are still in follow-up evaluation, whether or not they have achieved HBeAg seroconversion.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
Kaplan–Meier curve for the cumulative probabilities of developing serologic recurrence, defined as reappearance of HBeAg confirmed by HBeAg positivity in a consecutive sample, after HBeAg seroconversion. (A) Number of patients who have not developed serologic recurrence and are still in follow-up evaluation. (B) Number of patients who are still in follow-up evaluation, whether or not they have developed serologic recurrence.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
Kaplan–Meier curve for the cumulative probabilities of developing virologic recurrence, defined as an increase of HBV DNA to greater than 10,000 copies/mL after HBeAg seroconversion and previously having been less than 10,000 copies/mL, confirmed in a consecutive sample. (A) Number of patients who have not developed virologic recurrence and are still in follow-up evaluation. (B) Number of patients who are still in follow-up evaluation, whether or not they have developed virologic recurrence. Eight patients had ongoing viral replication with HBV-DNA levels greater than 10,000 copies/mL despite the achievement of HBeAg seroconversion and were excluded from this analysis.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

5. Figure 4
Proportion of patients who developed serologic and/or virologic recurrence after nucleos(t)ide analogue-induced HBeAg seroconversion, and causes of serologic and/or virologic recurrence, specified per treatment regimen.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions